Stockreport

Erasca: Strong Data Overshadowed By A Patient Death And A Patent Fight [Seeking Alpha]

Erasca, Inc.  (ERAS) 
PDF Recent Phase 1 data for ERAS-0015 demonstrated strong target engagement and favorable unconfirmed response rates, but a Grade 5 pneumonitis event and IP risk triggered [Read more]